Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 1:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 608 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Nonsmall Cell Lung Cancer, Stage IIIB Clear all
Completed Phase 1 Interventional

Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Cancer

NCT00005023
View directory record Official record
Conditions
Breast Cancer, Lung Cancer, Ovarian Cancer
Interventions
HER-2/neu peptide vaccine, sargramostim
Biological
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 30, 2017 · Synced Oct 23, 2026, 1:10 AM EDT
Completed Phase 2 Interventional

Soblidotin in Treating Patients With Progressive Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT00061854
View directory record Official record
Conditions
Lung Cancer
Interventions
soblidotin
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
3
States / cities
Waterbury, Connecticut • Detroit, Michigan • New York, New York
Source: ClinicalTrials.gov public record
Updated May 16, 2012 · Synced Oct 23, 2026, 1:10 AM EDT
Completed Phase 2 Interventional

A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)

NCT01031225
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
STA 9090
Drug
Lead sponsor
Synta Pharmaceuticals Corp.
Industry
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
21
States / cities
Tucson, Arizona • Hot Springs, Arkansas • Duarte, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2014 · Synced Oct 23, 2026, 1:10 AM EDT
Completed Phase 2 Interventional

Epothilone D in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Has Not Responded to Platinum-Based Chemotherapy

NCT00081107
View directory record Official record
Conditions
Lung Cancer
Interventions
epothilone D
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 5, 2013 · Synced Oct 23, 2026, 1:10 AM EDT
Completed Phase 2 Interventional Results available

Cetuximab in Treating Patients With Recurrent or Stage IIIB or Stage IV Lung Cancer

NCT00103207
View directory record Official record
Conditions
Lung Cancer
Interventions
cetuximab
Biological
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
157
States / cities
Aurora, Colorado • Colorado Springs, Colorado • Denver, Colorado + 107 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 23, 2026, 1:10 AM EDT
Completed Phase 2 Interventional

Randomized Study Of CP-675,206 or Best Supportive Care Immediately After Platinum-Based Therapy For Non-Small Cell Lung Cancer (NSCLC)

NCT00312975
View directory record Official record
Conditions
Carcinoma, Non-small-cell Lung
Interventions
CP-675,206, best supportive care
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
14
States / cities
Bentonville, Arkansas • Fayetteville, Arkansas • Orange, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2012 · Synced Oct 23, 2026, 1:10 AM EDT
Completed Not applicable Interventional

Palliative Care Teaching Sessions for Family Caregivers of Patients With Non-Small Cell Lung Cancer

NCT00827333
View directory record Official record
Conditions
Lung Cancer
Interventions
educational intervention, questionnaire administration, end-of-life treatment/management, psychosocial assessment and care, quality-of-life assessment
Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
372 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Aug 2, 2016 · Synced Oct 23, 2026, 1:10 AM EDT
Completed Phase 2 Interventional

Bryostatin 1 Plus Paclitaxel in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-small Cell Lung Cancer

NCT00005849
View directory record Official record
Conditions
Lung Cancer
Interventions
bryostatin 1, paclitaxel
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
10
States / cities
Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Oct 23, 2026, 1:10 AM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Sorafenib + Carboplatin and Docetaxel in First Line Treatment of Stage IIIB/IV NSCLC

NCT00647426
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Sorafenib + Docetaxel/Carboplatin
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 22, 2019 · Synced Oct 23, 2026, 1:10 AM EDT
Completed Not applicable Interventional Results available

Massage Therapy in Treating the Symptoms of Patients With Locally Advanced or Metastatic Cancer

NCT00253708
View directory record Official record
Conditions
Cancer
Interventions
management of therapy complications, massage therapy, pain therapy, psychosocial assessment and care, quality-of-life assessment
Procedure
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 7, 2017 · Synced Oct 23, 2026, 1:10 AM EDT
Completed Phase 3 Interventional Results available

Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer

NCT01107626
View directory record Official record
Conditions
Lung Cancer
Interventions
Paclitaxel, Carboplatin, Bevacizumab, Pemetrexed Disodium Heptahydrate
Drug · Biological
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
1,516 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2021
U.S. locations
434
States / cities
Anniston, Alabama • Fairbanks, Alaska • Fairfield, California + 312 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2023 · Synced Oct 23, 2026, 1:10 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Dyadic Yoga Intervention in Improving Physical Performance and Quality of Life in Patients With Stage I-IV Non-small Cell Lung or Esophageal Cancer Undergoing Radiotherapy and Their Caregivers

NCT03948100
View directory record Official record
Conditions
Esophageal Carcinoma, Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8, Stage IA2 Lung Cancer AJCC v8, Stage IA3 Lung Cancer AJCC v8, Stage IB Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Educational Intervention, Quality-of-Life Assessment, Questionnaire Administration, Yoga
Other · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 23, 2026, 1:10 AM EDT
Completed No phase listed Observational

Study of Symptoms Caused by Cancer and Cancer Therapy in Patients With Invasive Breast, Lung, Prostate, or Colorectal Cancer

NCT00303914
View directory record Official record
Conditions
Breast Cancer, Cognitive/Functional Effects, Colorectal Cancer, Lung Cancer, Pain, Prostate Cancer, Psychosocial Effects of Cancer and Its Treatment
Interventions
assessment of therapy complications, cognitive assessment, psychosocial assessment and care
Procedure
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
2,310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
32
States / cities
Chicago, Illinois • Evanston, Illinois • Elkhart, Indiana + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Oct 23, 2026, 1:10 AM EDT
Terminated Not applicable Interventional

FDG-PET/CT Scans in Patients With Stage IIIB or Stage IV NSCLC Undergoing Chemotherapy

NCT00424138
View directory record Official record
Conditions
Lung Cancer
Interventions
FDG
Radiation
Lead sponsor
American College of Radiology Imaging Network
Network
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 11, 2018 · Synced Oct 23, 2026, 1:10 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)

NCT02864992
View directory record Official record
Conditions
Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification, Lung Adenocarcinoma Stage IIIB/IV
Interventions
Tepotinib
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
337 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
39
States / cities
Duarte, California • Encinitas, California • Orange, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 23, 2026, 1:10 AM EDT
Completed Phase 1 Interventional

Docetaxel, Cisplatin, and Erlotinib Hydrochloride in Treating Patients With Stage I-III Non-small Cell Lung Cancer Following Surgery

NCT00254384
View directory record Official record
Conditions
Recurrent Lung Non-Small Cell Carcinoma, Stage IA Lung Non-Small Cell Carcinoma AJCC v7, Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage IIA Lung Non-Small Cell Carcinoma AJCC v7, Stage IIB Lung Non-Small Cell Carcinoma AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7
Interventions
Cisplatin, Docetaxel, Erlotinib, Erlotinib Hydrochloride, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 5, 2024 · Synced Oct 23, 2026, 1:10 AM EDT
Terminated Phase 1 Interventional Results available

Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies

NCT02706392
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Triple-Negative Breast Carcinoma, Recurrent Acute Lymphoblastic Leukemia, Recurrent Mantle Cell Lymphoma, Refractory Chronic Lymphocytic Leukemia, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Lung Non-Small Cell Cancer AJCC v7, Unresectable Lung Non-Small Cell Carcinoma
Interventions
Laboratory Biomarker Analysis, ROR1 CAR-specific Autologous T-Lymphocytes
Other · Biological
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 31, 2022 · Synced Oct 23, 2026, 1:10 AM EDT
Completed Phase 1 Interventional

Photodynamic Therapy During Surgery in Treating Patients With Non-small Cell Lung Cancer That Can Be Removed by Surgery

NCT01854684
View directory record Official record
Conditions
Recurrent Non-Small Cell Lung Carcinoma, Stage IIA Non-Small Cell Lung Carcinoma, Stage IIB Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer
Interventions
Temoporfin, Therapeutic Conventional Surgery, Photodynamic Therapy, Laboratory Biomarker Analysis, Pharmacological Study
Drug · Procedure · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jul 22, 2022 · Synced Oct 23, 2026, 1:10 AM EDT
Completed No phase listed Observational

Growth Factor Levels in the Blood of Patients Undergoing Radiation Therapy for Epithelial Cancer

NCT00897793
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer, Prostate Cancer
Interventions
venipuncture, radiation therapy
Procedure · Radiation
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
3
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 12, 2013 · Synced Oct 23, 2026, 1:10 AM EDT
Completed Phase 2 Interventional Results available

FDG-Labeled PET Scan in Planning Chemotherapy in Treating Patients With Stage IIIB or IV Non-Small Cell Lung Cancer

NCT00564733
View directory record Official record
Conditions
Malignant Pleural Effusion, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
carboplatin, docetaxel, gemcitabine hydrochloride, paclitaxel, computed tomography, positron emission tomography, fludeoxyglucose F 18, imaging biomarker analysis
Drug · Procedure · Radiation + 1 more
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 10, 2017 · Synced Oct 23, 2026, 1:10 AM EDT
Terminated Phase 3 Interventional Results available

Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung Cancer

NCT00738881
View directory record Official record
Conditions
Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
Interventions
Erlotinib Hydrochloride, Pemetrexed Disodium
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
268
States / cities
Scottsdale, Arizona • Fort Smith, Arkansas • Antioch, California + 176 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2015 · Synced Oct 23, 2026, 1:10 AM EDT
Completed Phase 2 Interventional Results available

S0635: Erlotinib and Bevacizumab in Stage IIIB and IV Bronchioloalveolar Carcinoma

NCT00436332
View directory record Official record
Conditions
Lung Cancer
Interventions
bevacizumab, erlotinib hydrochloride
Biological · Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 120 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2019
U.S. locations
148
States / cities
Antioch, California • Berkeley, California • Burlingame, California + 109 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2020 · Synced Oct 23, 2026, 1:10 AM EDT
Terminated Not applicable Interventional Results available

Genetic Sequencing-Informed Targeted Therapy in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer

NCT02132884
View directory record Official record
Conditions
Malignant Pericardial Effusion, Malignant Pleural Effusion, Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
cytology specimen collection procedure, therapeutic procedure, targeted therapy, laboratory biomarker analysis
Other · Procedure · Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
Not listed
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 4, 2019 · Synced Oct 23, 2026, 1:10 AM EDT
Completed Phase 1 Interventional

Dose Escalating Study With BAY43-9006 With Carboplatin, Paclitaxel and Bevacizumab in Untreated Stage IIIb Non-small Cell Lung Cancer (NSCLC)

NCT01069328
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Lung Cancer
Interventions
Nexavar (Sorafenib, BAY43-9006), Bevacizumab, Paclitaxel, Carboplatin
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
Rochester, Minnesota • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 13, 2013 · Synced Oct 23, 2026, 1:10 AM EDT